Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. Our breakthrough technology is challenging that and aims to treat multiple tumors, in parallel, during a single session.
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. RefleXion will work together with chemotherapy, immunotherapy and targeted drugs for potentially better outcomes.
HAYWARD, Calif., July 16, 2019 — RefleXionTM Medical, a biotargeting oncology company using each cancer’s unique biology as a means to destroy it, today announced that Thorsten Melcher, Ph.D., has joined the executive team in the role of Chief Business Officer. “Thorsten is a top-tier oncology industry leader with a proven track record of designing and executing […]
RefleXion Medical is preparing to ramp up production of its cancer-fighting machine, which leverages positron emission tomography (PET) imaging to target cancer with radiation therapy. The Hayward-based company hopes to have FDA clearance for its medical machine by year’s end, propelled by a $60 million credit facility from Oxford Finance LLC granted earlier this month. […]
In prior posts of this blog, we have approached the story of metastatic cancer from a number of different angles. We discussed what metastatic cancer is, and why it is a deadly disease. We discussed in depth that drugs such as chemotherapy and immunotherapy are the most common treatment for metastatic cancer because they can attack both visible tumors and […]